Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + AVD + radiotherapy
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, External Beam Radiation
01
Overview
Tislelizumab is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), developed to minimize FcγR binding and reduce resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2 interactions with PD-1, it restores T-cell function and promotes immune-mediated antitumor responses. Tislelizumab is generally well tolerated and has been studied in combination with radiotherapy for various cancers, including metastatic castration-resistant prostate cancer (mCRPC), hepatocellular carcinoma (HCC), bladder cancer, and others. Radiotherapy is a non-pharmacological therapy that uses ionizing radiation to kill or control malignant cells. The "AVD" regimen refers to the chemotherapy combination of doxorubicin, vinblastine, and dacarbazine—commonly used in Hodgkin lymphoma treatment protocols but not specifically referenced in the provided search results as being combined with tislelizumab or radiotherapy.
- Brand names
- Tevimbra
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on tislelizumab + AVD + radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + AVD + radiotherapy.